Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilization and cognition in subjects with mild to moderate Alzheimer's Disease (AD)
rosiglitazone
49653/461
NCT00265148
Alzheimer's Disease
Phase 2
 
A follow-on study AVA104617 was conducted.
September 2013

Powered by ideaPoint, Inc.